Burning Rock Biotech Limited American Depositary Receipt

Burning Rock Biotech Limited American Depositary Receipt represents a precision oncology company specializing in next-generation sequencing (NGS)-based diagnostics for cancer therapy selection. The company provides advanced cancer genotyping technologies for both tissue and liquid biopsies, integrating proprietary assay biochemistry, bioinformatics, a patented laboratory information management system, and expansive genomic databases. Its comprehensive product portfolio includes Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others, supporting companion diagnostics for targeted therapy and immunotherapy, tumor diagnosis, minimal residual disease monitoring, recurrence prediction, and susceptibility tests. Burning Rock operates through three key segments: Central Laboratory business serving smaller hospitals, In-hospital business targeting larger hospitals, and Pharma research and development services. This two-pronged commercial infrastructure enhances accessibility in the oncology diagnostics market. Founded in 2014 and headquartered in Guangzhou, China, with a CLIA-certified and CAP-accredited high-complexity laboratory in Irvine, California, USA, it positions itself as a global leader in NGS-driven precision medicine solutions.